Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06963398
PHASE1
A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.
Official title: A Phase 1 Study, Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10529 Monotherapy in KRAS G12D Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
520
Start Date
2025-05-15
Completion Date
2029-08-30
Last Updated
2025-05-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
HS-10529
Participants in all subjucts will receive HS-10529